Theravance Biopharma said that it is advancing TD-0903, a lung-selective nebulized Janus kinase inhibitor (JAKi) into clinical development to assess its utility in preventing the cytokine storm associated with acute lung injury (ALI) in patients hospitalized due to COVID-19, with the ultimate goal of preventing progression to acute respiratory distress syndrome (ARDS).   “In response to the unprecedented healthcare challenges presented by the emergence of COVID-19, we have combined our imm...